2-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]ethyl methanesulfonate | 331746-50-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]ethyl methanesulfonate
• 英文别名: 2-[2-(4-Methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]ethyl methanesulfonate
• CAS: 331746-50-0
• 化学式: C₁₄H₁₇NO₅S
• 分子量: 311.359
• InChiKey: UICCIDHSWMGIBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  87
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]ethyl methanesulfonate 、 tert-butyl (2S,3S)-1-(4-tert-butylphenyl)-3-[(3-hydroxyphenyl)methyl]-4-oxoazetidine-2-carboxylate 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists

  摘要：

  A novel class of azetidinone acid-derived dual PPAR alpha/gamma agonists has been synthesized for the treatment of diabetes and dyslipidemia. The preferred stereochemistry in this series for binding and functional agonist activity against both PPAR alpha and PPAR gamma receptors was shown to be 3S,4S. Synthesis, in vitro and in vivo activities of compounds in this series are described. A high-yielding method for N-arylation of azetidinone esters is also described. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.126

文献信息

• Novel heterocyclic derivatives and medicinal use thereof
  申请人：——

  公开号：US20040180924A1

  公开（公告）日：2004-09-16

  The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I′) 1 wherein R 1 is a hydrogen atom or C 1-6 alkyl, R 2 is —CO—C(R 4 )═C(R 4 )—R 5 wherein R 4 is a hydrogen atom or C 1-4 alkyl, and R 5 is C 4-8 alkyl, C 2-8 alkenyl, aryl or aromatic heterocycle, —CO—C≡C—R 6 wherein R 6 is C 1-8 alkyl and the like, R 3 is a hydrogen atom or C 1-4 alkyl, X is an oxygen atom or a sulfur atom, R 20 is optionally substituted phenyl, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I′) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases and an agent for the prophylaxis or treatment of syndrome X.

  本发明的新型杂环衍生物是一种具有公式（I'）的新型杂环衍生物，其中R1是氢原子或C1-6烷基，R2是—CO—C(R4)═C(R4)—R5，其中R4是氢原子或C1-4烷基，R5是C4-8烷基、C2-8烯基、芳香族或芳香族杂环，—CO—C≡C—R6，其中R6是C1-8烷基等，R3是氢原子或C1-4烷基，X是氧原子或硫原子，R20是可选取代的苯基，n是1到4的整数，或其药学上可接受的盐。本发明的化合物（I'）可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐量改善剂、抗动脉硬化剂、抗肥胖剂、抗炎剂、预防或治疗PPAR介导的疾病的药剂和预防或治疗X综合征的药剂。
• Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：Cheng T. Peter

  公开号：US20070015797A1

  公开（公告）日：2007-01-18

  Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R 1 , R 2 , R 2a , R 2b , R 2c , R 3 , Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供了一些化合物，它们的结构如下：其中Q为C或N，A为O或S，Z为O或键，X为CH或N，R1、R2、R2a、R2b、R2c、R3、Y、x、m和n如此定义，这些化合物可用作抗糖尿病、降脂和抗肥胖药物。
• SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD
  申请人：Cheng T. W. Peter

  公开号：US20070287713A1

  公开（公告）日：2007-12-13

  wherein Z 1 is (CH 2 ) q or C═O; Z 2 is (CH 2 ) p or C═O; D is —CH═ or C═O or (CH 2 ) m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; A is (CH 2 ) x where x is 1 to 5, or A is (CH 2 ) x 1 , where x 1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH 2 ) x 2 —O—(CH 2 ) x 3 — where x 2 is 0 to 5 and x 3 is 0 to 5, provided that at least one of x 2 and x 3 is other than 0; B is a bond or is (CH 2 ) x 4 where x 4 is 1 to 5; X is CH or N; X 2 is C, N, O or S; X 3 is C, N, O or S; X 4 is C, N, O or S; X 5 is C, N, O or S; X 6 is C, N, O or S; provided that at least one of X 2 , X 3 , X 4 X 5 and X 6 is N; and at least one of X 2 , X 3 , X 4 X 5 and X 6 is C. R 1 is H or alkyl; R 2 is H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; R 2a , R 2b and R 2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; and R 3 , E, Z and Y are as defined herein.

  其中Z1为(CH2)q或C═O；Z2为(CH2)p或C═O；D为—CH═或C═O或(CH2)m，其中m为0、1、2或3；n=0、1或2；p=1或2；q=0、1或2；Q为C或N；A为(CH2)x，其中x为1到5，或A为(CH2)x1，其中x1为1到5，具有烯丙基键或炔基键嵌入链中的任何位置，或A为—(CH2)x2—O—(CH2)x3—，其中x2为0到5，x3为0到5，前提是x2和x3中至少有一个不为0；B为键或(CH2)x4，其中x4为1到5；X为CH或N；X2、X3、X4、X5和X6为C、N、O或S；前提是X2、X3、X4、X5和X6中至少有一个为N；并且X2、X3、X4、X5和X6中至少有一个为C。R1为H或烷基；R2为H、烷基、烷氧基、卤素、氨基、取代氨基或氰基；R2a、R2b和R2c可以相同也可以不同，选择自H、烷基、烷氧基、卤素、氨基、取代氨基或氰基；而R3、E、Z和Y的定义如前所述。
• NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：EP1398313A1

  公开（公告）日：2004-03-17

  The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I') wherein R1 is a hydrogen atom or C1-6 alkyl, R2 is -CO-C(R4)=C(R4)-R5 wherein R4 is a hydrogen atom or C1-4 alkyl, and R5 is C4-8 alkyl, C2-8 alkenyl, aryl or aromatic heterocycle, -CO-C≡C-R6 wherein R6 is C1-8 alkyl and the like, R3 is a hydrogen atom or C1-4 alkyl, X is an oxygen atom or a sulfur atom, R20 is optionally substituted phenyl, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I') of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases and an agent for the prophylaxis or treatment of syndrome X.

  本发明的新型杂环衍生物是具有式（I'）的新型杂环衍生物 其中 R1 是氢原子或 C1-6 烷基，R2 是 -CO-C(R4)=C(R4)-R5 其中 R4 是氢原子或 C1-4 烷基，R5 是 C4-8 烷基、C2-8 烯基、芳基或芳香杂环，-CO-C≡C-R6 其中 R6 是 C1-8 烷基等，R3 是氢原子或 C1-4 烷基，X 是氧原子或硫原子，R20 是任选取代的苯基，n 是 1 至 4 的整数，或其药学上可接受的盐。本发明的化合物（I'）可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐量改善剂、抗动脉硬化剂、抗肥胖剂、抗炎剂、预防或治疗 PPAR 介导的疾病的药物以及预防或治疗 X 综合征的药物。
• US6872732B2
  申请人：——

  公开号：US6872732B2

  公开（公告）日：2005-03-29